Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib.
Ryosuke ImaiYutaka TomishimaPublished in: Respirology case reports (2020)
Nintedanib, a tyrosine kinase inhibitor, is approved for the treatment of idiopathic pulmonary fibrosis. We report a case of left ventricular dysfunction in a patient with idiopathic pulmonary fibrosis treated with nintedanib, which recovered after cessation of nintedanib. Nintedanib may induce left ventricular dysfunction, and early recognition is important since this condition is potentially reversible.
Keyphrases
- idiopathic pulmonary fibrosis
- left ventricular
- interstitial lung disease
- heart failure
- hypertrophic cardiomyopathy
- acute myocardial infarction
- oxidative stress
- cardiac resynchronization therapy
- aortic stenosis
- case report
- mitral valve
- left atrial
- acute coronary syndrome
- newly diagnosed
- transcatheter aortic valve replacement
- drug administration
- catheter ablation